Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA

Cancer Gene Therapy

Volumn 16, Issue 3, 2009, Pages 217-226

  Mikhaylova, M ^a   Stasinopoulos, I ^a   Kato, Y ^a   Artemov, D ^a,b   Bhujwalla, Z M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Cyclooxygenase 2; MRI; Multicomponent cationic liposome; Optical imaging; siRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CYCLOOXYGENASE 2; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; GADOLINIUM PENTETATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOPLEX; LIPOSOME; MACROGOL; MACROGOL 2000; PEGYLATED CYCLOOXYGENASE 2 LIPOPLEX CONJUGATE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL DIFFERENTIATION; CELL VIABILITY; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY; LIVER; LUNG; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; SCID MOUSE; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CATIONS; CELL LINE, TUMOR; CONTRAST MEDIA; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GADOLINIUM DTPA; HUMANS; INJECTIONS, INTRAVENOUS; IRON; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; NEOPLASM PROTEINS; ORGANOMETALLIC COMPOUNDS; OXIDES; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 60149090385     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.79     Document Type: Article

References (32)

1. Wang D, DuBois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle 2007; 6: 682-685.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
3. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006; 6: 221-232.
4. Stasinopoulos I, O'Brien DR, Wildes F, Glunde K, Bhujwalla ZM. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res 2007; 5: 435-442.
5. Lasic DD. Colloid chemistry. Liposomes within liposomes. Nature 1997; 387: 26-27.
6. Zelphati O, Szoka Jr FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13: 1367-1372.
7. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002; 1: 337-346.
8. Sioud M, Sorensen DR. Systemic delivery of synthetic siRNAs. Methods Mol Biol 2004; 252: 515-522.
9. Cardoso AL, Simoes S, de Almeida LP, Pelisek J, Culmsee C, Wagner E et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med 2007; 9: 170-183.
10. Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: preparation and in vitro test. Int J Pharm 2007; 331: 160-166.
11. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.
12. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002; 22: 129-150.
13. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312: 1220-1225.
14. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766.
15. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006; 17: 117-124.
16. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007; 67: 2938-2943.
17. Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q et al. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006; 25: 889-907.
18. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007; 28: 1434-1442.
19. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004; 10: 7721-7726.
20. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005; 12: 634-643.
21. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007; 13: 372-377.
22. Cailleau R, Young R, Olive M, Reeves Jr WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53: 661-674.
23. Dass CR, Walker TL, Burton MA. Liposomes containing cationic dimethyl dioctadecyl ammonium bromide: formulation, quality control, and lipofection efficiency. Drug Deliv 2002; 9: 11-18.
24. Fesus L, Thomazy V, Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 1987; 224: 104-108.
25. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747.
26. Li SD, Huang L. Targeted delivery of antisense oligodeoxy-nucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006; 3: 579-588.
27. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Therapy 2006; 13: 1222-1234.
28. Yu W, Pirollo KF, Rait A, Yu B, Xiang LM, Huang WQ et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Therapy 2004; 11: 1434-1440.
29. Frank JA, Zywicke H, Jordan EK, Mitchell J, Lewis BK, Miller B et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002; 9(Suppl. 2): S484-S487.
30. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46(12 Part 1): 6387-6392.
31. Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1996; 1281: 139-149.
32. Zelphati O, Uyechi LS, Barron LG, Szoka Jr FC. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1998; 1390: 119-133.